Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

NCT02282371 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Cancer

Interventions

DRUG: Cetuximab
DRUG: BYL719
RADIATION: IMRT (Intensity-Modulated Radiation Therapy)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]